Goldman Sachs Group Inc Coherus Bio Sciences, Inc. Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 2,077,643 shares of CHRS stock, worth $3.26 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,077,643
Previous 2,160,031 3.81%
Holding current value
$3.26 Million
Previous $3.74 Million 42.18%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$0.99 - $1.8 $81,564 - $148,298
-82,388 Reduced 3.81%
2,077,643 $2.16 Million
Q2 2024

Aug 13, 2024
BUY
$1.58 - $2.51 $703,822 - $1.12 Million
445,457 Added 25.98%
2,160,031 $3.74 Million
Q1 2024

May 15, 2024
BUY
$2.02 - $3.14 $1.77 Million - $2.75 Million
876,999 Added 104.71%
1,714,574 $4.1 Million
Q4 2023

Feb 13, 2024
SELL
$1.59 - $3.85 $769,855 - $1.86 Million
-484,186 Reduced 36.63%
837,575 $2.79 Million
Q3 2023

May 14, 2024
BUY
$3.74 - $5.45 $1.81 Million - $2.64 Million
484,186 Added 57.81%
1,321,761 $4.94 Million
Q3 2023

Nov 14, 2023
BUY
$3.74 - $5.45 $2.98 Million - $4.34 Million
797,200 Added 151.97%
1,321,761 $4.94 Million
Q2 2023

May 14, 2024
SELL
$3.79 - $8.3 $577,857 - $1.27 Million
-152,469 Reduced 22.52%
524,561 $2.24 Million
Q2 2023

Aug 14, 2023
SELL
$3.79 - $8.3 $577,857 - $1.27 Million
-152,469 Reduced 22.52%
524,561 $2.24 Million
Q1 2023

May 14, 2024
SELL
$5.89 - $10.52 $144,670 - $258,392
-24,562 Reduced 3.5%
677,030 $4.63 Million
Q1 2023

May 11, 2023
SELL
$5.89 - $10.52 $144,670 - $258,392
-24,562 Reduced 3.5%
677,030 $4.63 Million
Q4 2022

May 14, 2024
SELL
$5.69 - $10.07 $401,884 - $711,244
-70,630 Reduced 9.15%
701,592 $5.56 Million
Q4 2022

Feb 13, 2023
SELL
$5.69 - $10.07 $401,884 - $711,244
-70,630 Reduced 9.15%
701,592 $5.56 Million
Q3 2022

May 14, 2024
BUY
$7.17 - $13.87 $1.23 Million - $2.38 Million
171,247 Added 28.49%
772,222 $7.42 Million
Q3 2022

Nov 10, 2022
BUY
$7.17 - $13.87 $1.23 Million - $2.38 Million
171,247 Added 28.49%
772,222 $7.42 Million
Q2 2022

May 14, 2024
SELL
$5.86 - $13.23 $1.39 Million - $3.13 Million
-236,600 Reduced 28.25%
600,975 $4.35 Million
Q2 2022

Aug 15, 2022
BUY
$5.86 - $13.23 $740,211 - $1.67 Million
126,316 Added 26.61%
600,975 $4.35 Million
Q1 2022

May 16, 2022
SELL
$10.92 - $16.41 $967,260 - $1.45 Million
-88,577 Reduced 15.73%
474,659 $6.13 Million
Q4 2021

Feb 14, 2022
SELL
$15.81 - $18.99 $1.41 Million - $1.69 Million
-89,250 Reduced 13.68%
563,236 $8.99 Million
Q3 2021

Nov 10, 2021
BUY
$12.68 - $17.79 $8.27 Million - $11.6 Million
652,486 New
652,486 $10.5 Million

Others Institutions Holding CHRS

# of Institutions
135
Shares Held
77.9M
Call Options Held
40.7K
Put Options Held
50.1K
View Full List

About Coherus BioSciences, Inc.

CHRS Quotes by TradingView
  • Ticker CHRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,724,600
  • Market Cap $122M
  • Description
  • Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...
More about CHRS
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email